Rapamycin is the latest in a series of new immunosuppressants. Because of its unique capacity to inhibit lymphokine signal transduction, the immune-modulating potentials of rapamycin appear to be different from the antecedent agents, Cyclosporine and FK506. This influence on the effector arm of the immune-response makes Rapamycin a suitable candidate for multiple-drug therapy in combination with Cyclosporine which acts earlier in the immunoresponse process. Rapamycin, unlike Cyclosporine and FK506, has been shown to affect B-cell functions and T-cell - B-cell signal pathways. The effect on antibody synthesis may explain Rapamycin induced unresponsiveness.
|Titolo:||IMMUNOPHARMACOLOGY OF RAPAMYCIN|
FERRARESSO, MARIANO (Primo)
|Settore Scientifico Disciplinare:||Settore MED/18 - Chirurgia Generale|
|Data di pubblicazione:||1992|
|Appare nelle tipologie:||01 - Articolo su periodico|